Phaseline

Targets › MDM2

MDM2 (E3 ubiquitin-protein ligase Mdm2): drug programs, companies and trials

6 programs from 6 companies in 20 trials: 10 Phase 1, 9 Phase 2, 1 Phase 3; Oncology; next expected readout Dec 2026.

E3 ubiquitin-protein ligase that mediates ubiquitination of p53/TP53, leading to its degradation by the proteasome. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding its transcriptional activation domain. (UniProt, Q00987)

Open in Phaseline: the race on MDM2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kartos TherapeuticsNavtemadlin (KRT-232)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 3Myelofibrosis; Polycythemia Vera; Endometrial Cancer; Diffuse Large B Cell Lymphoma …Dec 2026
Ascentage Pharma GroupAPG-115
MDM2 inhibitor
MDM2Phase 2T-Prolymphocytic Leukemia; Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Liposarcoma; Neuroblastoma …Jan 2027
Centre Leon BerardSiremadlin (HDM201)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 2Malignant Solid Tumor; Advanced Soft-tissue SarcomaFeb 2027
University of WashingtonCD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX
ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1Phase 2Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast CarcinomaApr 2027
Boehringer IngelheimBrigimadlin
MDM2 inhibitor
MDM2Phase 2Solid TumoursDec 2030
AeRang KimAlrizomadlin (APG-115)
Tumour suppressor p53/oncoprotein Mdm2 inhibitor
TP53, MDM2Phase 1Malignant Peripheral Nerve Sheath Tumor (MPNST)Oct 2027

Conditions

Acute Myeloid Leukemia (2) Anatomic Stage IV Breast Cancer AJCC v8 (2) Malignant Solid Tumor (1) Advanced Soft-tissue Sarcoma (1) T-Prolymphocytic Leukemia (1) Unresectable or Metastatic Melanoma or Advanced Solid Tumors (1) Liposarcoma (1) Neuroblastoma (1) Malignant Salivary Gland Cancer (1) Myelofibrosis (1) Polycythemia Vera (1) Endometrial Cancer (1)

Modalities

small molecule (4), mixed (2)

Companies

Centre Leon Berard (1) Ascentage Pharma Group (1) Kartos Therapeutics (1) University of Washington (1) AeRang Kim (1) Boehringer Ingelheim (1)

Related targets

TP53 (3) ENG (1) YBX1 (1) SOX2 (1) CDH3 (1) CD105 (1) YB1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.